Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response

被引:26
作者
Zhao, Lu [1 ]
Liu, Hao [1 ]
Wang, Yingchao [1 ]
Wang, Shufang [1 ]
Xun, Dejin [1 ]
Wang, Yi [1 ,2 ]
Cheng, Yiyu [1 ,2 ]
Zhang, Boli [2 ]
机构
[1] Zhejiang Univ, Pharmaceut Informat Inst, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, State Key Lab Component Based Chinese Med, Tianjin 301617, Peoples R China
来源
ENGINEERING | 2023年 / 20卷
基金
中国国家自然科学基金;
关键词
Xuanfeibaidu Formula; Multimodal identification; Inflammation; Macrophage activation; Macrophage migration; NF-KAPPA-B; ACTIVATION; RECOGNITION; EXPRESSION; COVID-19; BIOLOGY;
D O I
10.1016/j.eng.2021.09.007
中图分类号
T [工业技术];
学科分类号
08 ;
摘要
Xuanfeibaidu Formula (XFBD) is a Chinese medicine used in the clinical treatment of coronavirus disease 2019 (COVID-19) patients. Although XFBD has exhibited significant therapeutic efficacy in clinical prac-tice, its underlying pharmacological mechanism remains unclear. Here, we combine a comprehensive research approach that includes network pharmacology, transcriptomics, and bioassays in multiple model systems to investigate the pharmacological mechanism of XFBD and its bioactive substances. High-resolution mass spectrometry was combined with molecular networking to profile the major active substances in XFBD. A total of 104 compounds were identified or tentatively characterized, including fla-vonoids, terpenes, carboxylic acids, and other types of constituents. Based on the chemical composition of XFBD, a network pharmacology-based analysis identified inflammation-related pathways as primary tar-gets. Thus, we examined the anti-inflammation activity of XFBD in a lipopolysaccharide-induced acute inflammation mice model. XFBD significantly alleviated pulmonary inflammation and decreased the level of serum proinflammatory cytokines. Transcriptomic profiling suggested that genes related to macro-phage function were differently expressed after XFBD treatment. Consequently, the effects of XFBD on macrophage activation and mobilization were investigated in a macrophage cell line and a zebrafish wounding model. XFBD exerts strong inhibitory effects on both macrophage activation and migration. Moreover, through multimodal screening, we further identified the major components and compounds from the different herbs of XFBD that mediate its anti-inflammation function. Active components from XFBD, including Polygoni cuspidati Rhizoma, Phragmitis Rhizoma, and Citri grandis Exocarpium rubrum, were then found to strongly downregulate macrophage activation, and polydatin, isoliquiritin, and acteo-side were identified as active compounds. Components of Artemisiae annuae Herba and Ephedrae Herba were found to substantially inhibit endogenous macrophage migration, while the presence of ephedrine, atractylenolide I, and kaempferol was attributed to these effects. In summary, our study explores the pharmacological mechanism and effective components of XFBD in inflammation regulation via multi-modal approaches, and thereby provides a biological illustration of the clinical efficacy of XFBD.(c) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:63 / 76
页数:14
相关论文
共 61 条
[1]   Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3 [J].
Alexopoulou, L ;
Holt, AC ;
Medzhitov, R ;
Flavell, RA .
NATURE, 2001, 413 (6857) :732-738
[2]   Endothelium-derived toll-like receptor-4 is the key molecule in LPS-induced neutrophil sequestration into lungs [J].
Andonegui, G ;
Bonder, CS ;
Green, F ;
Mullaly, SC ;
Zbytnuik, L ;
Raharjo, E ;
Kubes, P .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (07) :1011-1020
[3]   Platelets express functional Toll-like receptor-4 [J].
Andonegui, G ;
Kerfoot, SM ;
McNagny, K ;
Ebbert, KVJ ;
Patel, KD ;
Kubes, P .
BLOOD, 2005, 106 (07) :2417-2423
[4]  
[Anonymous], 2021, U.S.
[5]   COVID-19: Discovery, diagnostics and drug development [J].
Asselah, Tarik ;
Durantel, David ;
Pasmant, Eric ;
Lau, George ;
Schinazi, Raymond F. .
JOURNAL OF HEPATOLOGY, 2021, 74 (01) :168-184
[6]  
Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI [10.1056/NEJMoa2007764, 10.1056/NEJMc2022236]
[7]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[8]  
Cao B, 2020, NEW ENGL J MED, V382, P1787, DOI [10.1056/NEJMoa2001282, 10.1056/NEJMc2008043]
[9]   The Immunology of Macrophage Activation Syndrome [J].
Crayne, Courtney B. ;
Albeituni, Sabrin ;
Nichols, Kim E. ;
Cron, Randy Q. .
FRONTIERS IN IMMUNOLOGY, 2019, 10
[10]   mpeg1 promoter transgenes direct macrophage-lineage expression in zebrafish [J].
Ellett, Felix ;
Pase, Luke ;
Hayman, John W. ;
Andrianopoulos, Alex ;
Lieschke, Graham J. .
BLOOD, 2011, 117 (04) :E49-E56